Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Enlivex ( (ENLV) ).
On March 23, 2026, Enlivex announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for Allocetra to treat moderate-to-severe age-related primary knee osteoarthritis. The clearance, based on encouraging Phase 1/2a data in 134 patients showing durable, clinically meaningful benefits up to six months, allows the company to launch a global, multicenter, randomized, double-blind, placebo-controlled Phase 2b trial.
The upcoming Phase 2b study will test intra-articular Allocetra injections against placebo, with statistically powered endpoints focused on pain reduction and improved physical function at three and six months, alongside quality-of-life and mobility measures. As Enlivex’s first late-stage global trial approval under its dual-engine value creation model, the decision marks a significant step in targeting a large unmet need in knee osteoarthritis, a condition affecting more than 32 million Americans and expected to grow sharply with an aging population, potentially enhancing both its clinical and commercial profile.
The most recent analyst rating on (ENLV) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Neutral.
The score is held down mainly by weak financial performance (no revenue, ongoing losses, and persistent cash burn despite improvement) and a valuation profile dominated by negative earnings. Technicals provide partial support due to a clear uptrend, but overbought momentum readings add near-term risk.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Ltd., based in Nes-Ziona, Israel, is a “quality longevity” company developing Allocetra, a clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. The company also operates a dual-engine model that couples its therapeutic pipeline with a prediction markets treasury strategy built around the RAIN protocol on Arbitrum.
Average Trading Volume: 352,693
Technical Sentiment Signal: Strong Sell
Current Market Cap: $242.1M
For a thorough assessment of ENLV stock, go to TipRanks’ Stock Analysis page.